Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Status epilepticus and tiagabine therapy: Review of safety data and epidemiologic comparisons
Autore:
Shinnar, S; Berg, AT; Treiman, DM; Hauser, WA; Hesdorffer, DC; Sackellares, JC; Leppik, I; Sillanpaa, M; Sommerville, KW;
Indirizzi:
Montefiore Med Ctr, Albert Einstein Coll Med, Comprehens Epilepsy Mangement Ctr, Bronx, NY 10467 USA Montefiore Med Ctr Bronx NY USA 10467 Mangement Ctr, Bronx, NY 10467 USA Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467USA Montefiore Med Ctr Bronx NY USA 10467 ed, Dept Neurol, Bronx, NY 10467USA Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467USA Montefiore Med Ctr Bronx NY USA 10467 ed, Dept Pediat, Bronx, NY 10467USA Abbott Labs, Neurosci Franchise, N Chicago, IL 60064 USA Abbott Labs N Chicago IL USA 60064 sci Franchise, N Chicago, IL 60064 USA Turku Univ Hosp, Dept Child Neurol, TYKS, FIN-20520 Turku, Finland Turku Univ Hosp Turku Finland FIN-20520 , TYKS, FIN-20520 Turku, Finland Univ Minnesota, Minneapolis, MN USA Univ Minnesota Minneapolis MN USAUniv Minnesota, Minneapolis, MN USA MINCEP Epilepsy Care, Minneapolis, MN USA MINCEP Epilepsy Care Minneapolis MN USA ilepsy Care, Minneapolis, MN USA Vet Adm Med Ctr, Gainesville, FL 32602 USA Vet Adm Med Ctr Gainesville FLUSA 32602 d Ctr, Gainesville, FL 32602 USA Univ Florida, Dept Neurol, Gainesville, FL USA Univ Florida Gainesville FL USA lorida, Dept Neurol, Gainesville, FL USA Univ Florida, Dept Neurosci, Gainesville, FL USA Univ Florida GainesvilleFL USA rida, Dept Neurosci, Gainesville, FL USA Columbia Univ, Sch Publ Hlth, Div Epidemiol, New York, NY USA Columbia Univ New York NY USA Publ Hlth, Div Epidemiol, New York, NY USA Columbia Univ, Gertrude H Sergievsky Ctr, Dept Neurol, New York, NY 10027 USA Columbia Univ New York NY USA 10027 , Dept Neurol, New York, NY 10027 USA Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08903 USA Univ Med & Dent New Jersey New Brunswick NJ USA 08903 swick, NJ 08903 USA No Illinois Univ, Dept Biol Sci, De Kalb, IL 60115 USA No Illinois Univ De Kalb IL USA 60115 ept Biol Sci, De Kalb, IL 60115 USA
Titolo Testata:
EPILEPSIA
fascicolo: 3, volume: 42, anno: 2001,
pagine: 372 - 379
SICI:
0013-9580(200103)42:3<372:SEATTR>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
NONCONVULSIVE STATUS EPILEPTICUS; GABA-UPTAKE INHIBITOR; RECURRENT FEBRILE SEIZURES; COMPLEX PARTIAL SEIZURES; ABSENCE SEIZURES; EPILEPSY; CHILDHOOD; CHILDREN; RISK;
Keywords:
tiagabine; GABA; status epilepticus; epidemiology; electroencephalography;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Shinnar, S Montefiore Med Ctr, Albert Einstein Coll Med, Comprehens Epilepsy Mangement Ctr, 111 E 210th St, Bronx, NY 10467 USA Montefiore Med Ctr 111 E 210th St Bronx NY USA 10467 10467 USA
Citazione:
S. Shinnar et al., "Status epilepticus and tiagabine therapy: Review of safety data and epidemiologic comparisons", EPILEPSIA, 42(3), 2001, pp. 372-379

Abstract

Purpose: To determine whether an increased risk of status epilepticus (SE)and complex partial status epilepticus (CPSE) is associated with tiagabine(TGB) therapy. Methods: Thirteen cases in which an EEG, performed on patients with altered mental status taking TGB, was reported to demonstrate spike-and-wave discharges (SWDs) were reviewed by a panel of experts. In addition, all cases of suspected SE from TGB clinical trials were reviewed, The occurrence of SEin four epidemiologic cohorts from Rochester, Minnesota, Turku, Finland, Bronx, New York, and New Haven, Connecticut was analyzed as an external comparison. Results: Review of the 13 cases with reported SWDs found that the majorityhad had prior EEGs with similar findings, and only three were thought to have electrographic evidence of SE. There was no difference in the frequencyof SE or CPSE in the placebo-controlled clinical trials between the TGB-treated (1.0% SE, 0.8% CPSE) and placebo-treated (1.5% SE, 1.5% CPSE) groups. The 5% frequency of SE and 3% frequency of CPSE in the TGB-treated patients in the long-term safety studies, which included 2,248 patients, were verysimilar to the rates of occurrence of SE and CPSE in the four external cohorts. The major risk factor for the occurrence of SE and CPSE in all groupswas a prior episode of SE (p < 0.0001). Conclusions: Over a 3-year period, SE will occur in 5-10% of patients withepilepsy not in remission. At highest risk are those who have had a prior episode of SE. Treatment with TGB in recommended doses does not increase the risk of SE in patients with partial seizures.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 13:51:24